Page last updated: 2024-09-04

sclareol and Acute Lung Injury

sclareol has been researched along with Acute Lung Injury in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Deng, JS; Hsieh, YH; Huang, GJ; Huang, SS; Liao, JC; Pan, HP	1

Other Studies

1 other study(ies) available for sclareol and Acute Lung Injury

Article	Year
Sclareol ameliorate lipopolysaccharide-induced acute lung injury through inhibition of MAPK and induction of HO-1 signaling. International immunopharmacology, 2017, Volume: 44 Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Cells, Cultured; Cytokines; Diterpenes; Heme Oxygenase-1; Inflammation Mediators; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred ICR; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase Type II; Signal Transduction	2017

Article

Year

Sclareol ameliorate lipopolysaccharide-induced acute lung injury through inhibition of MAPK and induction of HO-1 signaling.

International immunopharmacology, 2017, Volume: 44

Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Cells, Cultured; Cytokines; Diterpenes; Heme Oxygenase-1; Inflammation Mediators; Lipopolysaccharides; Lung; Male; Mice; Mice, Inbred ICR; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase Type II; Signal Transduction

2017